Advanced Practitioner Society for Hematology and Oncology (APSHO) Hematologic Malignancies (Sep, 2017)
In-Person Event
Sep 23, 2017
Philadelphia, Pennsylvania, USASpeakers
OVERVIEW
Advanced Practitioner Society for Hematology and Oncology (APSHO) Hematologic Malignancies is organized by Advanced Practitioner Society for Hematology and Oncology (APSHO) and would be held on Sep 23, 2017 at Sheraton Philadelphia Society Hill Hotel, Philadelphia, Pennsylvania, United States of America.
The target audience for this medical event for Oncologists. This CME Conference has been approved with a maximum of 6.00 AMA PRA Category 1 Credits.
Conference Objectives are :
• Identify the mechanism of action for novel agents used for the treatment of hematological malignancies including Multiple Myeloma, CLL, Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL).
• List monitoring parameters for toxicities associated with newer agents used to treat multiple myeloma, CLL, HL, and NHL.
• Describe the signs of early and serious toxicity that providers and patients need to be aware of when initiating therapy with new agents for multiple myeloma, CLL, HL and NHL.
• Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings.
• Anticipate and identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome.
• Identify strategies for encouraging patient adherence to oral therapeutics.
• Discuss the pivotal role and necessary expertise of the AP as a vital part of the inter-professional oncology/hematology team.
Additional details will be posted as soon as they are available.
The target audience for this medical event for Oncologists. This CME Conference has been approved with a maximum of 6.00 AMA PRA Category 1 Credits.
Conference Objectives are :
• Identify the mechanism of action for novel agents used for the treatment of hematological malignancies including Multiple Myeloma, CLL, Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL).
• List monitoring parameters for toxicities associated with newer agents used to treat multiple myeloma, CLL, HL, and NHL.
• Describe the signs of early and serious toxicity that providers and patients need to be aware of when initiating therapy with new agents for multiple myeloma, CLL, HL and NHL.
• Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings.
• Anticipate and identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome.
• Identify strategies for encouraging patient adherence to oral therapeutics.
• Discuss the pivotal role and necessary expertise of the AP as a vital part of the inter-professional oncology/hematology team.
Additional details will be posted as soon as they are available.
KEY DATES
23 Sep, 2017
Event Start Date
23 Sep, 2017
Event End Date
SPECIALITIES
Hematology Blood and Marrow TransplantOncologySUGGESTED HOTELS
CONFERENCE VENUE
Sheraton Philadelphia Society Hill Hotel
Quick Links